Sarepta's Worst Week: A Black Box, 500 Pink Slips, and a Stock in Crisis
Sarepta slapped the FDA's most severe safety warning on its gene therapy Elevidys after patient deaths, then cut 500 workers in the same week. With the stock down 80% and $1 billion in debt looming, the leading Duchenne muscular dystrophy company is fighting for survival.
When a company's gene therapy starts killing patients, everything changes fast.
Sarepta Therapeutics just hit a wall that few biotech companies survive intact. In a single week, the company added the FDA's most severe safety warning to its flagship drug, laid off roughly 500 employees (about a third of its workforce), and watched its stock price crater. For a company that was supposed to be the savior of Duchenne muscular dystrophy, this is a gut punch of historic proportions.
The Drug That Was Supposed to Change Everything
Elevidys was a landmark. Approved in 2023, it became the first gene therapy ever cleared for Duchenne muscular dystrophy (DMD), a devastating genetic disease that progressively destroys muscles in young boys. The therapy works by delivering a shortened version of the dystrophin gene (the one DMD patients are missing) directly into cells using a viral vector, essentially a hollowed-out virus repurposed as a delivery truck.
The concept is elegant: one IV infusion, one shot at producing the protein these kids desperately need. And for a while, the results looked promising. Three-year data from the Phase 3 EMBARK trial showed roughly a 70% reduction in the rate of functional decline. Sarepta's stock soared. Revenue followed. In 2025, Elevidys pulled in nearly $900 million in sales, helping push total company revenue past $2.2 billion.
Then the deaths started.
When the Delivery Truck Crashes
The viral vector that makes gene therapy possible also makes it dangerous. Think of it this way: you're sending a package into the body's most heavily guarded neighborhoods. Sometimes the immune system doesn't just inspect the package; it burns the whole building down.
That's essentially what happened in multiple patients. Two non-ambulatory teenage DMD patients died of acute liver failure within weeks to months of receiving Elevidys. A third patient died from the same cause in a related clinical trial for limb-girdle muscular dystrophy, which uses the same viral delivery platform (called AAVrh74). One of the deceased patients also had a concurrent cytomegalovirus infection, which may have compounded the liver damage.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Out of roughly 140 non-ambulatory patients treated worldwide, two fatal liver failures translates to an incidence of about 1–2% in that population. For a one-time therapy with no undo button, those odds are terrifying.
The FDA Drops the Hammer
The agency's response was swift and layered. First came a request that Sarepta suspend Elevidys distribution entirely while safety labeling was updated. Then came clinical holds on all trials using the AAVrh74 platform, freezing Sarepta's limb-girdle muscular dystrophy pipeline in its tracks.
The centerpiece of the regulatory action: a boxed warning (commonly called a "black box warning"), which is the FDA's nuclear option for drug labeling. It's reserved for risks so serious that doctors and patients need to see them before anything else. The warning flags acute liver injury, acute liver failure, and death.
The FDA also narrowed the approved patient population. Non-ambulatory patients (those who've lost the ability to walk) are no longer eligible. Only ambulatory DMD patients aged four and older can receive the therapy now. New monitoring requirements mandate weekly liver function tests for three months after treatment, plus a post-marketing study tracking about 200 patients for at least a year.
This isn't just a label tweak. It's a fundamental redrawing of who Elevidys is for.
The Financial Freefall
You can trace the commercial damage in the quarterly numbers. In Q1 2025, Elevidys generated $375 million in revenue. By Q4, that had collapsed to $110 million. Sarepta suspended shipments to non-ambulatory patients in June 2025, and the revenue cliff followed immediately.
Q1 2026 showed total company revenue dipping slightly to $730.8 million, with management explicitly blaming "a lower volume of Elevidys sales due to our updated label that only includes the ambulatory patient population." The math is unforgiving: fewer eligible patients means fewer infusions means less money.
Despite $2.2 billion in 2025 revenue, Sarepta posted a net loss of $713 million for the year. The company ended with about $1 billion in cash, but there's a ticking clock: about $158.6 million in convertible notes comes due in 2027, after the company refinanced most of its original 2027 debt in 2025. CEO Doug Ingram didn't mince words, reportedly saying that failing to restructure would "risk our long-term viability."
One-Third of the Company, Gone
The 500-person layoff isn't just cost-cutting. It's a strategic pivot disguised as a restructuring. Sarepta is targeting more than $400 million in annual savings by combining headcount reductions with deep cuts to its R&D pipeline.
The biggest casualty beyond people: Sarepta is pausing or killing most of its limb-girdle muscular dystrophy gene therapy programs, the very pipeline that was supposed to prove AAVrh74 could work across multiple diseases. Instead, the company is pivoting toward siRNA therapies (a different technology that uses small RNA molecules to silence disease-causing genes) for conditions like myotonic dystrophy, pulmonary fibrosis, and Huntington's disease.
It's a tacit admission that the gene therapy platform they built the company around may not be safe enough to expand.
What This Means for DMD Families
For the Duchenne community, this is agonizing. Elevidys remains available for ambulatory patients with enhanced monitoring, and it still has the strongest long-term efficacy data of any DMD treatment. But the promise of gene therapy for the sickest patients, those who've already lost the ability to walk, is now off the table.
The competitive landscape offers some hope. Regenxbio's RGX-202, a next-generation gene therapy using a different vector design, is planning a regulatory submission in mid-2026. Dyne Therapeutics' DYNE-251, an exon-skipping therapy that earned FDA Breakthrough Therapy designation in August 2025, is also approaching a filing. These alternatives don't carry the same AAV liver risks, which suddenly matters a lot more than it did a year ago.
Analysts have noticed. The consensus rating on Sarepta is Hold, with at least one firm (Wainwright) maintaining a Sell. Nobody's betting on a comeback.
A Cautionary Tale Written in Real Time
Sarepta's crisis isn't unprecedented. The FDA slapped boxed warnings on all approved CAR-T therapies in 2024 after reports of secondary T-cell cancers. Novartis's gene therapy Zolgensma already carries a boxed warning for liver injury. The pattern is becoming clear: gene therapies can do extraordinary things, but the viral vectors that deliver them carry risks that sometimes don't show up until thousands of patients have been treated.
For Sarepta, the question isn't whether Elevidys works. The three-year data suggests it does, at least for ambulatory patients. The question is whether a company that just lost a third of its workforce, most of its pipeline ambitions, and nearly all of its stock market value can survive long enough to prove it.
Clinical & Regulatory5 min read
CRISPR Just Got Cleared for Toddlers. Yes, Toddlers.
The FDA just approved a CRISPR gene therapy for kids as young as two, a world first. Casgevy's expansion into toddlers could prevent the silent organ damage that sickle cell disease inflicts from infancy, but delivering a treatment this complex to tiny patients is a whole different challenge.
